.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Understanding the Evolving Role of PI3K Inhibitors in the Treatment of Follicular Lymphoma

EP. 1: Dr. Kahl on Selecting Between PI3K Inhibitors in Follicular Lymphoma

July 6th 2021

Brad S. Kahl, MD, discusses selecting between PI3K inhibitors in follicular lymphoma.

EP. 2: Dr. Leonard on the Potential for Combinations With PI3K Inhibitors in Follicular Lymphoma

July 6th 2021

John P. Leonard, MD, discusses the potential for combination regimens with PI3K inhibitors in follicular lymphoma.

EP. 3: Dr. Leonard on the Future of PI3K Inhibitors in Follicular Lymphoma

July 7th 2021

John P. Leonard, MD, discusses the future of PI3K inhibitors in follicular lymphoma.

EP. 4: Dr. Kahl on Differences in Mechanisms of Action of PI3K Inhibitors in Follicular Lymphoma

July 7th 2021

Brad S. Kahl, MD, discusses the differences between mechanisms of action of PI3K inhibitors in follicular lymphoma.

EP. 5: The Evolving Role of PI3K Inhibitors in the Treatment of Follicular Lymphoma

August 13th 2021

On June 18, 2021, OncLive® brought together a group of oncologists who specialize in the treatment of follicular lymphoma to participate in a virtual workshop to discuss the evolving role of PI3K inhibitors in the treatment of follicular lymphoma. This article summarizes key data about PI3K inhibitors as a therapeutic target as well as insights from stakeholder discussions regarding this topic.